Use of hemostatic powder in treatment of upper gastrointestinal bleeding: a systematic review and meta-analysis

Abstract

Background and study aims TC-325 is a novel mineral hemostatic powder that creates a mechanical barrier by absorbing blood components and promoting clotting. Recently approved for use in humans, it has shown promise for treatment of upper gastrointestinal bleeding (UGIB). However, because there have been no large studies of TC-325, its true efficacy and safety profile remain unknown. We performed a systematic review and meta-analysis to determine the safety and efficacy of TC-325 in treating UGIB, based on rates of initial hemostasis, rebleeding, and adverse events (AEs).

Methods We searched the MEDLINE/PubMed, EMBASE, CENTRAL, Latin-American and Caribbean Health Sciences Literature databases, as well as the gray literature, to identify articles describing use of TC-325 up to October 2018. Primary outcomes were initial hemostasis and rebleeding. AEs were described as a secondary outcome. Risk of bias was assessed with international scores.

Results We identified 2077 records after removal of duplicates. We included 50 studies, involving a collective total of 1445 patients, in the quantitative synthesis. Primary hemostasis and rebleeding rates were 90.7 % and 26.1 %, respectively. Subgroup analyses showed similar results. Only eight AEs were reported.

Conclusions TC-325 appears to be a safe, effective treatment for UGIB. The overall rate of initial hemostasis after TC-325 use is high, regardless of etiology of bleeding or whether TC-325 is used as a primary or rescue therapy. Although it is also associated with high rebleeding rates, rates of AEs and equipment failure after TC-325 use are extremely low.

• References

• 1 Abougergi MS, Travis AC, Saltzman JR. et al. The in-hospital mortality rate for upper GI hemorrhage has decreased over 2 decades in the United States: a nationwide analysis. Gastrointest Endosc 2015; 81: 882-888.e1
• 2 Sostres C, Lanas A. Epidemiology and Demographics of Upper Gastrointestinal Bleeding: Prevalence, Incidence, and Mortality. Gastrointest Endosc Clin N Am 2011; 21: 567-581
• 3 van Leerdam ME. Epidemiology of acute upper gastrointestinal bleeding. Best Pract Res Clin Gastroenterol 2008; 22: 209-224
• 4 Rotondano G. Epidemiology and diagnosis of acute nonvariceal upper gastrointestinal bleeding. Gastroenterol Clin North Am 2014; 43: 643-663
• 5 Hearnshaw SA, Logan RFA, Lowe D. et al. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011; 60: 1327-1335
• 6 Chen YI, Barkun AN. Hemostatic powders in gastrointestinal bleeding. a systematic review. Gastrointest Endosc Clin N Am 2015; 25: 535-552
• 7 Baracat F, Moura E, Bernardo W. et al. Endoscopic hemostasis for peptic ulcer bleeding: systematic review and meta-analyses of randomized controlled trials. Surg Endosc 2016; 30: 2155-2168
• 8 Ribeiro IB, Rezende DT, Madruga Neto AC. et al. Endoscopic dual therapy for giant peptic ulcer hemorrhage. Endoscopy 2018; 50: E316-E317
• 9 Lera ME, Minata MK, Duarte RB. et al. Massive bleeding after plastic stent removal during ERCP: what’s next?. Endoscopy 2017; 49: E303-E304
• 10 Chaves DM, Costa FF, Matuguma S. et al. Splenic artery pseudoaneurysm treated with thrombin injection guided by endoscopic ultrasound. Endoscopy 2012; 44 (Suppl. 02) E99-100
• 11 Lau JYW, Barkun A, Fan D. et al. Challenges in the management of acute peptic ulcer bleeding. Lancet (London, England) 2013; 381: 2033-2043
• 12 Garber A, Jang S. Novel therapeutic strategies in the management of non-variceal upper gastrointestinal bleeding. Clin Endosc 2016; 49: 421-424
• 13 Holster IL, Van Beusekom HMM. et al. Effects of a hemostatic powder hemospray on coagulation and clot formation. Endoscopy 2015; 98: 638-645
• 14 Moher D, Liberati A, Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535-b2535
• 15 Liberati A, Altman DG, Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700
• 16 Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996; 17: 1-12
• 17 Wells GA, Shea B, OʼConnel D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
• 18 Borenstein M, Hedges L, Higgins J. et al. Comprehensive meta-analysis [Internet]. Englewood, NJ; 2013 Available at https://www.meta-analysis.com
• 19 Moola S, Munn Z, Tufanaru C. et al. Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). Joanna Briggs Institute Reviewer’s Manual. The Joanna Brig 2017. Available at https://reviewersmanual.joannabriggs.org/
• 20 Nova da Costa LS, Marson FP. et al. Use of hemostatic powder (tc-325) in patients with upper gastrointestinal bleeding at a tertiary center: a case series. Gastrointest Endosc 2018; 87: AB173
• 21 da Costa Martins B, Scomparin RC, Bento LH. et al. Preliminary results of a randomized controlled trial comparing hemostatic powder versus optimal clinical treatment in the management of gastrointestinal bleeding from malignancy. Gastrointest Endosc 2018; 87: AB415-AB416
• 22 Ting MSR, Lim LL, Doshi B. et al. Experience of novel endoscopic hemostasis with hemospray in a tertiary medical centre in patients with acute non-variceal upper gastrointestinal bleeding. J Gastroenterol Hepatol 2016; 31: 7-441
• 23 Sonthalia N, Jain SS, Surude RG. et al. Use of hemospray for gastrointestinal bleeding: A single tertiary care centre experience from Western India. Indian J Gastroenterol 2016; 35 (Suppl 1): A85
• 24 Sokpon M, Tata A, Bernasconi M. et al. Expérience de l’utilisation de la poudre Hémospray^® dans la prise en charge des hémorragies digestives sévères dans un centre hospitalier général. J Africain d’Hépato-Gastroentérologie 2016; 10: 125-128
• 25 Vivar RM, Valenzuela C, Gonzalez RG. et al. Safety and efficacy of Hemospray^® in upper gastrointestinal bleeding: Experience in a chilean academic hospital. Gastrointest Endosc 2016; 83: AB499
• 26 Nasr I, DeMartino S, Borrow D-M. et al. Hemospray: When should we plug the gap? A single centre UK experience. Gastrointest Endosc 2016; 83: AB500-AB501
• 27 Dhesi E, Lam V, Tang K. et al. Single-centre clinical experience of hemospray endotherapy in patients with acute upper gastrointestinal bleeding. United Eur Gastroenterol J 2015; 3: 146-687
• 28 Disney B, Kurup A, Muhammad H. et al. Hemospray use for the management of acute bleeding from upper gastrointestinal cancer: the Russells Hall experience. Gut 2015; 64: A71.3-A72
• 29 Widlak M, Wijesinghe H, Siau K. et al. Hemospray for acute upper gastrointestinal bleeding – a single centre experience. Gut 2015; 64: A225.1-A225
• 30 Dixon S, Tate D, Przemioslo R. et al. Hemospray may not reliably achieve hemostasis beyond 48 hours in acute upper gastrointestinal bleeding. Gut 2015; 64: A420.3-A421
• 31 Malik A, Duane P, Eadala P. et al. Use of hemospray for non variceal upper gastrointestinal bleed in a district general hospital. Gut 2015; 64: A65.3-A66
• 32 Chen Y-I, Lu Y, Wyse J. et al. (Hemospray^TM) versus standard of care in managing malignant gastrointestinal bleeding: A pilot randomized clinical trial. Am J Gastroenterol 2017; 112: S285-S319
• 33 Jang S, Parsi MA, Stevens T. et al. Use of hemospray in intractable upper GI bleeding: U.S. Single Center Experience. Gastrointest Endosc 2015; 81: AB453
• 34 Minelli GrazioliL, Rando G, Lombardi L. et al. Hemospray as first-line treatment for upper gi tumoral bleeding in emergency endoscopy. Report of three cases. Dig Liver Dis 2015; 47: e157
• 35 Mangiavillano B, Arena M, Morandi E. et al. Use of hemospray powder in the acute upper GI bleeding. Dig Liver Dis 2013; 45: S203
• 36 Sagar N. Early clinical experience of the effectiveness of hemospray in achieving haemostasis in patients with acute non-variceal bleeding. United Eur Gastroenterol J 2014; 2: A329
• 37 Ali R, Carr-Locke D, Komanduri S. et al. Hemospray for refractory gastrointestinal bleeding: Initial United States experience. Am J Gastroenterol 2014; 109: S585
• 38 Masci E, Arena M, Morandi E. et al. Upper gastrointestinal active bleeding ulcers: review of literature on the results of endoscopic techniques and our experience with Hemospray. Scand J Gastroenterol 2014; 49: 1290-1295
• 39 Disney B, Kurup AK, Ishaq S. et al. Initial experience with hemospray in the treatment of acute upper gastrointestinal bleeding. United Eur Gastroenterol J 2014; 2: A252
• 40 Thomson M, Urs A, Narula P. et al. The use and safety of a novel haemostatic spray in the endoscopic management of acute nonvariceal upper gastrointestinal bleeding in children. J Pediatr Gastroenterol Nutr 2018; 67: e47-e50
• 41 Ibrahim M, El-Mikkawy A, Abdel Hamid M. et al. Early application of haemostatic powder added to standard management for oesophagogastric variceal bleeding: A randomised trial. Gut 2018; 1-10
• 42 Pittayanon R, Rerknimitr R, Barkun A. Prognostic factors affecting outcomes in patients with malignant GI bleeding treated with a novel endoscopically delivered hemostatic powder. Gastrointest Endosc 2018; 87: 994-1002
• 43 Alzoubaidi D, Gulati S, Murino A. et al. Outcomes from an international multicentre registry of patients with gastrointestinal bleeding undergoing endoscopic treatment with hemospray. United Eur Gastroenterol J 2017; 5: A161-A836
• 44 Cahyadi O, Bauder M, Meier B. et al. Effectiveness of TC-325 (Hemospray) for treatment of diffuse or refractory upper gastrointestinal bleeding – a single center experience. Endosc Int Open 2017; 05: E1159-E1164
• 45 Kwek BEA, Ang TL, Ong PLJ. et al. TC-325 versus the conventional combined technique for endoscopic treatment of peptic ulcers with high-risk bleeding stigmata: A randomized pilot study. J Dig Dis 2017; 18: 323-329
• 46 Arena M, Masci E, Eusebi LH. et al. Hemospray for treatment of acute bleeding due to upper gastrointestinal tumours. Dig Liver Dis 2017; 49: 514-517
• 47 Hagel AF, Albrecht H, Nägel A. et al. The application of Hemospray in gastrointestinal bleeding during emergency endoscopy. Gastroenterol Res Pract 2017; 2017: 6-8
• 48 Giles H, Lal D, Gerred S. et al. Efficacy and safety of TC-325 (HemosprayTM) for non-variceal upper gastrointestinal bleeding at Middlemore Hospital: the early New Zealand experience. N Z Med J 2016; 129: 38-43
• 49 Haddara S, Jacques J, Lecleire S. et al. A novel hemostatic powder for upper gastrointestinal bleeding: a multicenter study (the “GRAPHE” registry). Endoscopy 2016; 48: 1084-1095
• 50 Sinha R, Lockman KA, Church NI. et al. The use of hemostatic spray as an adjunct to conventional hemostatic measures in high-risk nonvariceal upper GI bleeding (with video). Gastrointest Endosc 2016; 84: 900-906.e3
• 51 Pittayanon R, Prueksapanich P, Rerknimitr R. The efficacy of Hemospray in patients with upper gastrointestinal bleeding from tumor. Endosc Int Open 2016; 04: E933-E936
• 52 Ibrahim M, El-Mikkawy A, Abdalla H. et al. Management of acute variceal bleeding using hemostatic powder. United Eur Gastroenterol J 2015; 3: 277-283
• 53 Szalai M, Kullmann T, Durcsán H. et al. [Hemospray: a novel therapeutic option in the management of acute upper gastrointestinal bleeding]. Orv Hetil 2015; 156: 528-531
• 54 Appleby R, Hoare J. PTH-022 Hemospray in a large tertiary nhs trust: a descriptive analysis of the first three years of use. Endoscopy 2017; A216.1-A216
• 55 Chen YI, Barkun AN, Soulellis C. et al. Use of the endoscopically applied hemostatic powder TC-325 in cancer-related upper GI hemorrhage: Preliminary experience (with video). Gastrointest Endosc 2012; 75: 1278-1281
• 56 Chen Y-I, Barkun A, Nolan S. Hemostatic powder TC-325 in the management of upper and lower gastrointestinal bleeding: a two-year experience at a single institution. Endoscopy 2015; 47: 167-171
• 57 Smith LA, Stanley AJ, Bergman JJ. et al. Hemospray application in nonvariceal upper gastrointestinal bleeding: results of the Survey to Evaluate the Application of Hemospray in the Luminal Tract. J Clin Gastroenterol 2014; 48: e89-92
• 58 Barkun A, Adam V, Martel M. TC-325 in the management of upper and lower GI bleeding: A two-year experience at a single institution. Value Heal 2014; 17: A749
• 59 Sulz MC, Frei R, Meyenberger C. et al. Routine use of Hemospray for gastrointestinal bleeding: Prospective two-center experience in Switzerland. Endoscopy 2014; 46: 619-624
• 60 Yau AHL, Ou G, Galorport C. et al. Safety and efficacy of Hemospray^® in upper gastrointestinal bleeding. Can J Gastroenterol Hepatol 2014; 28: 72-76
• 61 Ibrahim M, El-Mikkawy A, Mostafa I. et al. Endoscopic treatment of acute variceal hemorrhage by using hemostatic powder TC-325: A prospective pilot study. Gastrointest Endosc 2013; 78: 769-773
• 62 Holster IL, Kuipers EJ, Tjwa ETTL. Hemospray in the treatment of upper gastrointestinal hemorrhage in patients on antithrombotic therapy. Endoscopy 2013; 45: 63-66
• 63 Sung JJ, Luo D, Wu JC. et al. Early clinical experience of the safety and effectiveness of Hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding. Endoscopy 2011; 43: 291-295
• 64 Hanna MS. Hemospray in acute non-variceal upper gastrointestinal bleeding: First experiences in a uk teaching hospital. United Eur Gastroenterol J 2015; 3: 146-687
• 65 Thayalasekaran S, Dixon S, Mundre P. et al. PTH-054A Hemospray use in the management of upper gastrointestinal haemorrhage: a 2-year experience across 2 teaching hospitals in the north and south of england. Gut 2017; 66: A232.1-A232
• 66 Alzoubaidi D, Magee C, Gulati S. et al. Outcomes from an international multicentre registry of patients with gastrointestinal bleeding undergoing endoscopic treatment with hemospray. Gut 2017; 66: A65
• 67 Häberle MF, Senler WA, Saenz R. et al. Hemostatic spray powder, in critical gastrointestinal bleeding. a highly effective treatment alternative. Gastrointest Endosc 2017; 85: AB522
• 68 Eusebi LH, Arena M, Despott E. et al. Acute bleeding due to upper gastrointestinal tumors treated with hemospray: A case series from 4 European endoscopy centers. Gastrointest Endosc 2017; 85: AB457-AB458
• 69 Meng ZW, Marr KJ, Mohamed R. JPD. Study, Long-term efficacy and safety of TC-325 for malignancyrelated upper gastrointestinal bleeds a multicenter retrospective. Gastroenterology 2017; 85: S256
• 70 Sung JJY, Tsoi KKF, Lai LH. et al. Endoscopic clipping versus injection and thermo-coagulation in the treatment of non-variceal upper gastrointestinal bleeding: a meta-analysis. Gut 2007; 56: 1364-1373
• 71 Barkun A, Adam V, Martel M. TC-325 in the management of upper and lower GI bleeding: a two-year experience at a single institution. Value Health 2014; 17: A749
• 72 Yau AHL, Ou G, Galorport C. et al. Safety and efficacy of Hemospray® in upper gastrointestinal bleeding. Can J Gastroenterol Hepatol 2014; 28: 72-76
• 73 Sakai CM, Duarte RB, Baracat FI. et al. Endoscopic treatment of upper-GI ulcer bleeding with hemostatic powder spray. VideoGIE an Off video J Am Soc Gastrointest Endosc 2017; 2: 12-13
• 74 Baracat FI, Tranquillini CV, Brunaldi VO. et al. Hemostatic powder: a new ally in the management of postsphincterotomy bleeding. VideoGIE 2017; 2: 303-304
• 75 Giday S, Kim Y, Krishnamurty D. et al. Long-term randomized controlled trial of a novel nanopowder hemostatic agent (TC-325) for control of severe arterial upper gastrointestinal bleeding in a porcine model. Endoscopy 2011; 43: 296-299
• 76 Giday S, van Alstine W, van Vleet J. et al. Safety analysis of a hemostatic powder in a porcine model of acute severe gastric bleeding. Dig Dis Sci 2013; 58: 3422-3428
• 77 Sung JJY, Chiu PCY, Chan FKL. et al. Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: An update 2018. Gut 2018; 1757-1768
• 78 Gralnek I, Dumonceau J-M, Kuipers E. et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015; 47: a1-a46
• 79 Hemospray Label. 2018: 1-15 Available at https://www.cookmedical.com/data/IFU_PDF/12898_0318.PDF